GLTO | Galecto, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	10.85 - 11.70
52 Week Range	10.61 - 23.50
Beta	1.52
Implied Volatility	473.78%
IV Rank	N/A
Day's Volume	38,627
Average Volume	16,124
Shares Outstanding	1,085,210
Market Cap	12,110,944
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.48
Forward P/E Ratio	N/A
EPS	-23.25
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	GLTO

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

GLTO's peers: TERN, DAWN, ABOS, AMLX, MLTX, MOLN, CYT, CNTA, EWTX, LYEL, CGEM, GLUE, THRX, RVMD, ACRV, AADI, ALGS, SPRO, BOLT, CHRS, GRCL, NLTX, BLTE

*Chart delayed

Analyzing fundamentals for GLTO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see GLTO Fundamentals page.

Watching at GLTO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on GLTO Technicals page.